Researchers developed the crossNN AI model that classifies over 170 cancer types from DNA methylation data, achieving over 97% accuracy and enabling non-invasive diagnosis from liquid biopsies and tissue samples.
Key Details
- 1crossNN is a simple, explainable neural network AI trained on 8,000+ reference tumors and tested on 5,000+ tumors.
- 2Achieved 99.1% accuracy for brain tumor diagnosis; 97.8% accuracy across more than 170 tumor types from all organs.
- 3Uses DNA methylation profiles obtained from tissue or body fluids (e.g., cerebrospinal fluid), enabling some diagnoses to avoid surgical biopsies.
- 4Proven more accurate than previous AI solutions for tumor classification.
- 5The method is being prepared for clinical trials at all eight sites of the German Cancer Consortium.
- 6crossNN's workflow is fully explainable, meeting a key regulatory requirement for clinical adoption.
Why It Matters
crossNN demonstrates the potential of AI-driven, minimally invasive tumor diagnostics, which could complement imaging in cases where biopsy is too risky or impractical. Such models can improve diagnostic precision, reduce patient morbidity, and streamline selection of personalized treatments, impacting radiology workflows and multidisciplinary cancer care.
Source
EurekAlert
Related News
•EurekAlert
AI Accelerates Radiopharmaceuticals, Boosts Personalized Dosimetry in Cancer
Machine learning is driving advancements in radiopharmaceutical drug discovery and optimizing patient-specific dosimetry for precision cancer therapy.
•EurekAlert
Physicians Overly Trust Erroneous AI, Ignore Contradictory Evidence
Physicians tend to trust incorrect AI advice, even when evidence contradicts it, suggesting risks in clinical decision-making with AI tools.
•EurekAlert
Concerns Raised Over Unverified Datasets in AI Health Prediction Models
A new study finds widely used AI health prediction models are built on datasets with unverifiable origins, raising safety and validity concerns.